Safety and efficacy of tislelizumab plus chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma.

ABSTRACT:

SUBMITTER: Qiu HB 

PROVIDER: S-EPMC7705902 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature